The Paul Marks Lab: Publications

Visit PubMed for a full listing of Paul A. Marks’ journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Lee, J-H, Mahendran, A.,Yao, Y., Ngo, L., Venta-Perez, G., Choy, M., Kim, N., Ham, W-S, Breslow, R., & Marks, P.A. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl. Acad. Science,110:15704-15709, 2013

Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;188-193.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;5165-5170.

Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad USA. 2004;1241-1246.

Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res. 2004;137-168.

Shao G, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2004;18030-18035.

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredexin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005 (E-pub ahead of print).

Xu, W., Ngo, L., Perez, G., Dokmanovic, M., Marks, P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad Sci USA 103: 15540-15545, 2006.

Marks, P.A. Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anti-cancer drug. Nature Biotechnology, 25:84-90, 2007.

Xu, WS, Parmigiani, R.B. Marks, P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552, 2007.

Parmigiani, R.B., Xu, WS., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., and Marks, P.A. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci., USA, 105: 9633-9638, 2008.

Marks, P.A. and Xu, W.-S. Histone deacetylase inhibitors: Potential in cancer therapy. Jrl.CellularBiochemistry, 107:600-608,2009.